Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NMTC
NMTC logo

NMTC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy NeuroOne Medical Technologies Corp (NMTC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.020
1 Day change
52 Week Range
6.960
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

NMTC is not a strong buy right now for a beginner long-term investor with $50,000-$100,000. The stock shows some short-term stabilization, but the broader technical trend is still bearish, there are no fresh news catalysts, and the latest analyst target increase was largely a reverse-split adjustment rather than a fundamental upgrade. Given the lack of clear financials and the absence of strong proprietary buy signals, the best call is to hold off on buying now.

Technical Analysis

Current price is 3.03, roughly flat versus the prior close of 3.00. MACD histogram is slightly positive at 0.00728, but it is contracting, which does not confirm strong upward momentum. RSI_6 at 25.717 is low but still described as neutral in the provided data, so it is not yet a clean reversal signal. The moving average structure is bearish: SMA_200 > SMA_20 > SMA_5, indicating the longer-term trend remains weak. Price is trading just above S1 support at 2.971 and below the pivot at 3.169, so the stock is still in a fragile technical zone rather than a confirmed uptrend.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mildly bullish based on open interest, with a put-call ratio of 0.25, meaning call interest dominates. However, option volume is extremely light at 3 calls and 0 puts, so the current flow is too thin to treat as strong conviction. Implied volatility is very high at 460.45, with IV percentile 95.63 and IV rank 60, which reflects elevated expected movement but not necessarily directional confirmation. Overall, options lean bullish on positioning, but the activity level is too low to be a strong signal.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
1

Positive Catalysts

  • ["Analyst target was raised to $8 with a Buy rating remaining in place.", "Options open interest shows bullish skew with a 0.25 put-call ratio.", "MACD histogram is slightly above zero, suggesting the downtrend may be losing some momentum.", "Price is near support, which could attract tactical buying."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there are no event-driven catalysts.", "Technical trend is still bearish with SMA_200 > SMA_20 > SMA_5.", "No AI Stock Picker signal today.", "No recent SwingMax signal.", "No significant hedge fund or insider buying trends.", "No recent congress trading data.", "The stock trend model suggests a 70% chance of -1.09% next day and -14.98% next week."]

Financial Performance

No usable latest-quarter financial snapshot was provided, so I cannot assess revenue or earnings growth trends. The latest quarter season is not available in the data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Ladenburg raised the price target to $8 from $1.60 on 2026-05-13 and kept a Buy rating. However, the note explicitly says the change was due to the one-for-six reverse stock split, so this is more of a mechanical adjustment than a fresh improvement in fundamentals. Wall Street pros appear cautiously positive because the rating remains Buy, but the lack of additional analyst momentum and the split-driven target reset limit the strength of that bullish view.

Wall Street analysts forecast NMTC stock price to fall
1 Analyst Rating
Wall Street analysts forecast NMTC stock price to fall
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.020
sliders
Low
3
Averages
3
High
3
Current: 3.020
sliders
Low
3
Averages
3
High
3
Ladenburg
Buy
maintain
$8
AI Analysis
2026-05-13
Reason
Ladenburg
Price Target
$8
AI Analysis
2026-05-13
maintain
Buy
Reason
Ladenburg adjusted the firm's price target on NeuroOne Medical to $8 from $1.60 and keeps a Buy rating on the shares. It cites the one-for-six reverse stock split for the change.
JonesResearch
Justin Walsh
initiated
$1.50
2026-03-02
Reason
JonesResearch
Justin Walsh
Price Target
$1.50
2026-03-02
initiated
Reason
JonesResearch analyst Justin Walsh initiated coverage of NeuroOne Medical with a Buy rating and $1.50 price target. With a portfolio of four FDA-cleared products for the monitoring, recording, stimulation, and ablation of nervous tissue and support from distribution partner Zimmer Biomet (ZBH), the firm expects adoption of the OneRF Ablation System to continue at a steady pace, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for NMTC
Unlock Now

People Also Watch